RCEL
Avita Medical, Inc. Health Care Surgical & Medical Instruments & Apparatus Russell 3000
$15.65Close
$478.4MMarket cap
$7.85 – $16.7152-week range
Nov 5, 2026Next report · after the close
Highlights
Strengths
- Accumulation up-day volume 2.0× down-day volume over 50 sessions
Cautions
- Extended 5.1 ATR above its 50-day average
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
6%
1wk
up 0.9%
price change
1mo
up 33.4%
price change
12-month return
up 95%
total, dividends included
F-score
3 / 9
Weak
Altman Z
-8.01
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
down 9.1%
EBIT / enterprise value
Cheaper than
10%
of the market · expensive
Revenue growth
up 11%
year on year
EPS growth
—
latest quarter
Sales growth
up 18%
latest quarter · +14 pts
ROE
—
return on equity
Free cash margin
down 45%
-$32.2M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- profitability slipped from last year
- short-term liquidity weakened
- issued more shares
- gross margin narrowed
- profits backed by cash
- reduced long-term debt
- assets working harder
Repair signals
- Long-term debt down 100% ($0.0B → $0.0B)
Trade setup
ATR%
5.5%
$0.86 a day · 2×ATR $13.93
RS
—
vs the universe
Trend
—
trend template
Relative volume
1.7×
vs 50-day average
Up/down volume
2.00
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$16.6M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 16.0% over the year, from 26m to 31m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Gross margin narrowing Gross margin fell from 85.8% to 82.1%. The company is keeping less of each dollar of sales than it did a year ago.
Last reported
Aug 6, 2026
Financials
- Gross 82%
- Net -68%
- Free cash -45%
- Cash
- Long-term debt
| FY2020Jun 30, 2020 | FY2021Jun 30, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $14.3M | $29.2M | $34.4M | $50.1M | $64.3M | $71.6M |
| Gross margin | 79% | 80% | 82% | 84% | 86% | 82% |
| Operating income | -$42.7M | -$26.5M | -$27.5M | -$42.7M | -$56.6M | -$42.5M |
| Net income | -$42.0M | -$26.6M | -$26.7M | -$35.4M | -$61.8M | -$48.6M |
| Net margin | -295% | -91% | -77% | -71% | -96% | -68% |
| Earnings per share | -$2.07 | -$1.17 | -$1.07 | -$1.40 | -$2.39 | -$1.74 |
| Free cash flow | -$23.3M | -$26.8M | -$19.5M | -$39.4M | -$58.1M | -$32.2M |
| Free cash margin | -164% | -92% | -57% | -79% | -90% | -45% |
| Cash | $73.6M | $110.7M | $18.2M | $22.1M | $14.1M | $10.2M |
| Long-term debt | — | — | — | $39.8M | $42.2M | $0 |
| Shareholders' equity | $72.4M | $115.7M | $84.7M | $49.1M | $4.5M | -$16.6M |
| Shares outstanding | 21.47m | 24.90m | 25.21m | 25.68m | 26.35m | 30.57m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 14, 2026 | Quarterly ↗ | Mar 31, 2026 | 44d |
| Feb 12, 2026 | Annual ↗ | Dec 31, 2025 | 43d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 8, 2025 | Quarterly ↗ | Jun 30, 2025 | 39d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 13, 2025 | Annual ↗ | Dec 31, 2024 | 44d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 13, 2024 | Quarterly ↗ | Mar 31, 2024 | 43d |
| Feb 22, 2024 | Annual ↗ | Dec 31, 2023 | 53d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 11, 2026 | Material agreement ↗ |
| Aug 6, 2026 | Results ↗ |
| Jun 8, 2026 | Material agreement ↗ |
| Jun 4, 2026 | Director or officer change · Shareholder vote ↗ |
| May 14, 2026 | Results ↗ |
| May 1, 2026 | Director or officer change · Regulation FD ↗ |
| Feb 12, 2026 | Results ↗ |
| Jan 13, 2026 | Material agreement · Agreement ended · Results · New obligation · Unregistered share sale ↗ |
| Jan 5, 2026 | Director or officer change ↗ |
| Nov 6, 2025 | Material agreement · Results ↗ |
| Oct 17, 2025 | Director or officer change · Regulation FD ↗ |
| Aug 18, 2025 | Unregistered share sale ↗ |